|
Liver carcinoma
|
0.300 |
Biomarker
|
disease |
BEFREE |
We speculate that hsa_circRNA_104268/hsa-miR-214-3p/E2F2, hsa_circRNA_104168/hsa-miR-139-5p/HRAS, and hsa_circRNA_104769/hsa-miR-93-5p/JUN interaction pairs may play a vital role in HCC.
|
31222831 |
2020 |
|
Liver carcinoma
|
0.300 |
Biomarker
|
disease |
BEFREE |
Re-expression of PDCD4 inversely correlated with the level of miR-93 and attenuated the miR-93-induced promotion of cell growth in HCC.
|
28592130 |
2019 |
|
Liver carcinoma
|
0.300 |
ModifyingMutation
|
disease |
RGD |
Re-expression of PDCD4 inversely correlated with the level of miR-93 and attenuated the miR-93-induced promotion of cell growth in HCC.
|
28592130 |
2019 |
|
Liver carcinoma
|
0.300 |
Biomarker
|
disease |
BEFREE |
Specifically, miR-93 has been reported to play a crucial role in colorectal, breast, pancreatic, lung cancer and hepatocellular carcinoma.
|
29760585 |
2018 |
|
Liver carcinoma
|
0.300 |
Biomarker
|
disease |
BEFREE |
We obtained 545 DEmiRNA-DEmRNA pairs that consisted of 258 DEmRNAs and 28 DEmiRNAs in HCC. mir-424, miR-93 and miR-3607 are three hub DEmiRNAs of the HCC-specific DEmiRNA-DEmRNA interaction network.
|
30186744 |
2018 |
|
Liver carcinoma
|
0.300 |
Biomarker
|
disease |
BEFREE |
In summary, our work identified exosomal miR-93 as a novel biomarker for both diagnosis and prognosis in HCC.
|
29859935 |
2018 |
|
Liver carcinoma
|
0.300 |
AlteredExpression
|
disease |
BEFREE |
In addition, hsa-miR-93 was upregulated in <i>SNHG16</i>-overexpressed HCC cells to examine its effect on <i>SNHG16</i>-mediated cancer cell functional regulation in HCC.
|
30573973 |
2018 |
|
Liver carcinoma
|
0.300 |
AlteredExpression
|
disease |
BEFREE |
In conclusion, these results suggested that miR-93-5p overexpression contributes to hepatoma development by inhibiting PPARGC1A.
|
29361788 |
2018 |
|
Liver carcinoma
|
0.300 |
Biomarker
|
disease |
BEFREE |
miR-93 provides new insight into the molecular mechanisms of pathogenesis and progression in HCC and offer a potential therapeutic target for the treatment of HCC patients.
|
28748353 |
2017 |
|
Liver carcinoma
|
0.300 |
Biomarker
|
disease |
BEFREE |
Furthermore, the expression levels of miR-106b, miR-93 and miR-25 were positively correlated in HBV-associated HCC tissues (miR-106 vs miR-93, r = 0.75; miR-93 vs miR-25, r = 0.69; miR-106b vs miR-25, r = 0.33).
|
27298561 |
2016 |
|
Liver carcinoma
|
0.300 |
Biomarker
|
disease |
RGD |
Furthermore, the expression levels of miR-106b, miR-93 and miR-25 were positively correlated in HBV-associated HCC tissues (miR-106 vs miR-93, r = 0.75; miR-93 vs miR-25, r = 0.69; miR-106b vs miR-25, r = 0.33).
|
27298561 |
2016 |
|
Liver carcinoma
|
0.300 |
AlteredExpression
|
disease |
BEFREE |
Five of them (miR-148a, miR-375, miR-195, miR-497 and miR-378) were in hypermethylation and down-regulation status, while another five (miR-106b, miR-25, miR-93, miR-23a and miR-27a) were in hypomethylation and up-regulation status in HCC.
|
25424171 |
2015 |
|
Liver carcinoma
|
0.300 |
Biomarker
|
disease |
BEFREE |
We concluded that miR-93 stimulated cell proliferation, migration, and invasion through the oncogenic c-Met/PI3K/Akt pathway and also inhibited apoptosis by directly inhibiting PTEN and CDKN1A expression in human HCC.
|
25633810 |
2015 |